Screener
Candel Therapeutics, Inc. CADL Total Revenue
Discontinued — last reported Q4 '22
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Candel Therapeutics, Inc.’s 10-K, filed March 28, 2024.
- Filed
- Mar 28, 2024
- Fiscal year
- FY2023
- Accession
- 0000950170-24-037637
| Line item | YEAR ENDED DECEMBER 31, 2023 | YEAR ENDED DECEMBER 31, 2022 |
|---|---|---|
| Research and development service revenue, related party | — | $125 |
| Operating expenses: | ||
| Research and development | 24,506 | 20,787 |
| General and administrative | 13,885 | 14,060 |
| Total operating expenses | 38,391 | 34,847 |
| Loss from operations | (38,391) | (34,722) |
| Other income (expense): | ||
| Grant income | — | 48 |
Item 16. Form 10-K Summary
FAQ
- What is Candel Therapeutics, Inc.'s total revenue?
- Candel Therapeutics, Inc. (CADL) reported total revenue of $31K in Q4 2022.
- How has Candel Therapeutics, Inc.'s total revenue changed year-over-year?
- Candel Therapeutics, Inc.'s total revenue decreased by 0.0% year-over-year, from $31K to $31K.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Candel Therapeutics, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude